PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e for form 1449/PTO			Complete if Known			
				Application Number	10/594,105		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	March 28, 2005		
				First Named Inventor	Kevin G. Pinney, et		
				Art Unit	unknown		
				Examiner Name	unknown		
Sheet	1	of	1	Attorney Docket Number	BAYU-0002 WO/US (208614.00088)		

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	1	PIERRE B, De Montigny C, Chaput Y. A Role for the Serotonin System in the Mechanism of Action of Antidepressant Treatments: Preclinical Evidence, J Clin Psychiatry 51:4 (Supp), April 1990: 14-21.		
	2	GONZALEZ-HEYDRICH J, Peroutka S J. Serotonin Receptor and Reuptake Sites: Pharmacologic Significance, J Clin Psychology 51:4 (Supp), April 1990: 5-13.		
	3	HYTELL J. Citalpram-Pharmacological Profile of a Specific Serotonin Uptake Inhibitor with Antidepressant Activity, Prog. Neuro-Psychopharmacal & Biol. Psychiat. Vol. 6. 1982: 277-295.		
	4	MODELL J G, Katholi C R, Modell, J D, DePalma R L. Pharmacoepidemiology and Drug Utilization-Comprative Sexual Side Effects of Bupropion, Fluoxetine, Paroxetine, and Sertraline, Clinical Pharmacology & Therapeutics Vol. 61 Number 4, 1997: 476-487.		
	5	MUNSON P J, Rodbard D. Ligand: A Verstatile Computerized Approach for Characterization of Ligand-Binding Systems, Analytical Biochemistry 107, 1980: 220-239.		
	6	Lemberger L, Fuller R W, Zerbe R L. Use of Serotonin Uptake Inhibitors as Antidepressants, Clinical Neuropharmacology. Vol. 8 No. 4, 1985: 299-317.		
	7	ORJALES A, Mosquera R, Toledo A, Pumar M C, Garcia N, Cortizo L. Synthesis and Binding Studies of New [(Aryl)(aryloxy) methyl] piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters. Journal of Medicinal Chemistry Vol. 46 No. 25. 2003: 1512-1532.		
	8	DORSEY J M, Miranda M G, Cozzi N V, Pinney K G. Synthesis and biological evaluation of 2-(4-flourophenoxy)-2-phenyl-ethyl piperazines as serotonun-selective reuptake inhibitors with a potentially improved adverse reaction profile, Bioorganic & Medicinal Chemistry Vol 12, 2004: 1483-1491.		
	9	COZZI N V, Foley K F. Rapid and Efficient Method for Suspending Cells for Neurotransmiter Uptake Assays, BioTechniques 32, March 2002: 486-492.		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.